Johnson & Johnson (NYSE:JNJ – Get Free Report)’s share price was down 2% during trading on Monday after an insider sold shares in the company. The stock traded as low as $233.58 and last traded at $236.0610. Approximately 7,497,829 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 8,307,371 shares. The stock had previously closed at $240.87.
Specifically, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Analyst Ratings Changes
Several equities research analysts have weighed in on JNJ shares. Raymond James Financial raised their target price on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Johnson Rice upgraded shares of Johnson & Johnson from a “hold” rating to an “outperform” rating in a research note on Wednesday, May 13th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, April 15th. Finally, Bank of America raised their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $253.04.
Johnson & Johnson News Summary
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Johnson & Johnson announced a more than $1 billion investment in Jacksonville, Florida to expand U.S. Vision manufacturing, packaging, and distribution capacity. The move supports its Vision business, aligns with its larger U.S. manufacturing push, and signals continued commitment to domestic growth. Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- Positive Sentiment: The company also received attention for breakthrough IMAAVY (nipocalimab) data in warm autoimmune hemolytic anemia, with U.S. FDA Priority Review backing the therapy’s growth potential in a rare-disease market. IMAAVY Breakthrough And Priority Review Reframe Johnson And Johnson Growth Story
- Positive Sentiment: Johnson & Johnson is benefiting from renewed investor focus on its pipeline and capital deployment, including commentary that the stock has been gaining on improving sentiment around growth initiatives and dividend strength. Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained
- Neutral Sentiment: A separate article highlighted BlackBerry QNX being used in a Johnson & Johnson AI-powered heart pump, which is notable for innovation but does not appear to be a major direct stock-moving catalyst yet. BlackBerry QNX Extends Beyond Autos As Valuation Runs Ahead Of Targets
- Negative Sentiment: Broader market articles warning about an overheated AI/Nasdaq trade and general risk-off sentiment may be weighing on large-cap healthcare stocks like JNJ, even though they are not company-specific negatives. Today’s AI market hits all 5 warning signs that preceded 2000 Nasdaq crash.
Johnson & Johnson Stock Down 2.0%
The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The business’s fifty day simple moving average is $231.51 and its two-hundred day simple moving average is $227.35. The company has a market cap of $568.25 billion, a PE ratio of 27.29, a PEG ratio of 2.36 and a beta of 0.26.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same quarter in the previous year, the company earned $2.77 earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. The ex-dividend date of this dividend was Tuesday, May 26th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio is presently 61.97%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Evansbrook LLC increased its holdings in Johnson & Johnson by 1.3% in the first quarter. Evansbrook LLC now owns 5,453 shares of the company’s stock valued at $1,333,000 after buying an additional 71 shares in the last quarter. Wealthquest Corp increased its stake in shares of Johnson & Johnson by 11.9% during the first quarter. Wealthquest Corp now owns 10,152 shares of the company’s stock worth $2,482,000 after purchasing an additional 1,076 shares in the last quarter. Stillwater Private Wealth LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $365,000. DV Trading LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $379,000. Finally, Parallel Advisors LLC increased its stake in shares of Johnson & Johnson by 1.2% during the first quarter. Parallel Advisors LLC now owns 80,406 shares of the company’s stock worth $19,655,000 after purchasing an additional 966 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.
See Also
- Five stocks we like better than Johnson & Johnson
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
